# US 2016/0257957 A1 · Methods and compositions for treatment of angelman syndrome and autism spectrum disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257957 A1
- Document ID: US20160257957A1
- Status: Published application
- Kind: A1
- Application number: 15/158,995
- Filed: 2016-05-19
- Published: 2016-09-08
- Earliest claimed: 2010-03-02
- Assignees: President and Fellows of Harvard College; Children's Medical Center Corporation
- Applicants: President and Fellows of Harvard College; Children's Medical Center Corporation
- Inventors: Michael E. GREENBERG; Paul L. Greer
- Web page: https://patentgrep.com/patent/US20160257957A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/42: Oxazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4436: containing a heterocyclic ring having sulfur as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/54: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/30: Special therapeutic applications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for the treatment of Angelman Syndrome autism spectrum disorders are provided. The methods comprise administrating to a subject an agent that increases the expression of, or increases activity of, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) at neuronal synapses.

## Claims

### Claim 1

A method for treatment of Angelman Syndrome comprising administrating to a subject an agent that increases the expression of, or increases activity of, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) at neuronal synapses.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent that increases the expression of, or activity of, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) at neuronal synapses is an antagonist of metabotropic glutamate receptor subtype 5 (mGluR5).

### Claim 3 (depends on 2)

The method of claim 2, wherein the antagonist is selected from the group consisting of: LY293558; 2-methyl 6-[(1E)-2-phenylethynyl]-pyridine; 6-methyl-2(phenylazo)-3-pyridinol; (RS)-a-methyl-4carboxyphenylglycine (MCPG); 3S,4aR,6S,8aRS-6-((((1Htetrazole-5-yl) methyl)oxy)methyl)-1,2,3,4,4a,5,6,7,8,8adecahydroisoquinoline-3-carboxylic acid; 3S,4aR,6S,8aR-6((((1H-tetrazole-5-yl)methyl)oxy)methyl)-1,2,3,4,4a,5,6,7, 8,8a-decahydroisoquinoline-3-carboxylic acid; 3SR,4aRS, 6SR,8aRS-6-(((4-carboxy)phenyl)methyl)-1,2,3,4,4a,5,6,7, 8,8a-decahydroisoquinoline-3-carboxylic acid; and 3S,4aR, 6S,8aR-6-(((4-carboxy)-phenyl)methyl)-1,2,3,4,4a,5,6,7,8, 8a-decahydroisoquinoline-3-carboxylic acid.

### Claim 4 (depends on 2)

The method of claim 2, wherein the antagonist comprises 2-methyl-6-(phenylethynyl)-pyridine (MPEP) or 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP).

### Claim 5 (depends on 1)

The method of claim 1, wherein the agent that increases the expression of, or activity of, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) at neuronal synapses is selected from the group consisting of: diazoxide; cyclothiazide; 1-(1,3-benzodioxol-5-ylcarbonyl)-piperidine (1-BCP); S18986 [(S)-2,3-Dihydro-[3,4]Cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide); 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-S,S-dioxide (IDRA21); 7-chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S, dioxide; and an ampikine.

### Claim 6 (depends on 1)

The method of claim 1, wherein the agent inhibits the expression of, or inhibits the activity of, the synaptic protein activity-regulated cytoskeleton-associated protein (Arc).

### Claim 7 (depends on 6)

The method of claim 6, wherein the agent is an RNA interfering agent (RNAi).

### Claim 8 (depends on 7)

The method of claim 7, wherein the RNAi comprises SEQ ID NO: 9 or SEQ ID NO: 10.

### Claim 9 (depends on 1)

The method of claim 1, wherein the agent is selected from the group consisting of a small molecule, a nucleic acid, a protein, a peptide, an antibody, and an immunogenic fragment.

### Claim 10 (depends on 1)

The method of claim 1, wherein the agent is administered by a route selected from the group consisting of topical administration, enteral administration, and parenteral administration.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject is a human subject.

### Claim 12 (depends on 1)

The method of claim 1, wherein the agent is administered in a dose ranging from about 0.1 mg/kg to about 1000 mg/kg.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject has a loss of function a mutation in the E3 ubiquitin ligase gene UBe3A or a maternal deletion of chromosome 15q11-q13.

### Claim 14

A method for treatment of Angelman Syndrome comprising the steps of:
i) selecting a subject having a maternal deletion of chromosome 15q11-q13 or a loss of function mutation in the E3 ubiquitin ligase gene UBe3A; and
ii) administering an antagonist of metabotropic glutamate receptor subtype 5 (mGluR5) to the subject having Angelman syndrome caused by a the maternal deletion of chromosome 15q11-q13.

### Claim 15 (depends on 2)

The method of claim 2, wherein the antagonist is selected from the group consisting of: LY293558; 2-methyl 6-[(1E)-2-phenylethynyl]-pyridine; 6-methyl-2(phenylazo)-3-pyridinol; (RS)-a-methyl-4carboxyphenylglycine (MCPG); 3S,4aR,6S,8aRS-6-((((1Htetrazole-5-yl) methyl)oxy)methyl)-1,2,3,4,4a,5,6,7,8,8adecahydroisoquinoline-3-carboxylic acid; 3S,4aR,6S,8aR-6((((1H-tetrazole-5-yl)methyl)oxy)methyl)-1,2,3,4,4a,5,6,7, 8,8a-decahydroisoquinoline-3-carboxylic acid; 3SR,4aRS, 6SR,8aRS-6-(((4-carboxy)phenyl)methyl)-1,2,3,4,4a,5,6,7, 8,8a-decahydroisoquinoline-3-carboxylic acid; and 3S,4aR, 6S,8aR-6-(((4-carboxy)-phenyl)methyl)-1,2,3,4,4a,5,6,7,8, 8a-decahydroisoquinoline-3-carboxylic acid.

### Claim 16 (depends on 1)

The method of claim 1, wherein the antagonist comprises 2-methyl-6-(phenylethynyl)-pyridine (MPEP) or 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP).

### Claim 17 (depends on 1)

The method of claim 1, wherein the agent that increases the expression of, or activity of, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) at neuronal synapses is selected from the group consisting of: diazoxide; cyclothiazide; 1-(1,3-benzodioxol-5-ylcarbonyl)-piperidine (1-BCP); S18986 [(S)-2,3-Dihydro-[3,4]Cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide); 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-S,S-dioxide (IDRA21); 7-chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S, dioxide; and an ampikine.

### Claim 18 (depends on 1)

The method of claim 1, wherein the agent inhibits the expression of, or inhibits the activity of, the synaptic protein activity-regulated cytoskeleton-associated protein (Arc).

### Claim 19 (depends on 6)

The method of claim 6, wherein the agent is an RNA interfering agent (RNAi).

### Claim 20 (depends on 7)

The method of claim 7, wherein the RNAi comprises SEQ ID NO: 9 or SEQ ID NO: 10.
